



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

EMA/514077/2013  
EMA/H/C/000793

## EPAR summary for the public

---

### Olanzapine Cipla<sup>1</sup>

olanzapine

This is a summary of the European public assessment report (EPAR) for Olanzapine Cipla. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Olanzapine Cipla.

#### What is Olanzapine Cipla?

Olanzapine Cipla is a medicine that contains the active substance olanzapine. It is available as tablets (2.5, 5, 7.5, 10 and 15 mg).

Olanzapine Cipla is a 'generic medicine'. This means that Olanzapine Cipla is similar to a 'reference medicine' already authorised in the European Union (EU) called Zyprexa. For more information on generic medicines, see the question-and-answer document [here](#).

#### What is Olanzapine Cipla used for?

Olanzapine Cipla is used to treat adults with schizophrenia. Schizophrenia is a mental illness that has a number of symptoms including disorganised thinking and speech, hallucinations (hearing or seeing things that are not there), suspiciousness and delusions (mistaken beliefs). Olanzapine Cipla is also effective in maintaining improvement in patients who have responded to an initial course of treatment.

Olanzapine Cipla is also used to treat moderate to severe manic episodes (extremely high mood) in adults. It can also be used to prevent the recurrence of these episodes (when symptoms come back) in adults with bipolar disorder (a mental illness causing alternating periods of high mood and depression) who have responded to an initial course of treatment.

The medicine can only be obtained with a prescription.

---

<sup>1</sup> Previously known as Olanzapine Neopharma.



## How is Olanzapine Cipla used?

The recommended starting dose of Olanzapine Cipla depends on the disease being treated: 10 mg per day is used in schizophrenia and in the prevention of manic episodes, and 15 mg per day in the treatment of manic episodes, unless it is used with other medicines, in which case the starting dose can be 10 mg per day. The dose is adjusted depending on how well the patient responds to and tolerates the treatment. The usual dose range is between 5 and 20 mg per day. Patients over 65 years of age and patients who have problems with their liver or kidneys may need a lower starting dose of 5 mg per day.

## How does Olanzapine Cipla work?

The active substance in Olanzapine Cipla, olanzapine, is an antipsychotic medicine. It is known as an 'atypical' antipsychotic because it is different from the older antipsychotic medicines that have been available since the 1950s. Its exact mechanism of action is unknown, but it attaches to several receptors on the surface of nerve cells in the brain. This disrupts signals transmitted between brain cells by 'neurotransmitters', chemicals that allow nerve cells to communicate with each other. It is thought that olanzapine's beneficial effect is due to it blocking receptors for the neurotransmitters 5-hydroxytryptamine (also called serotonin) and dopamine. Since these neurotransmitters are involved in schizophrenia and bipolar disorder, olanzapine helps to normalise the activity of the brain, reducing the symptoms of these diseases.

## How has Olanzapine Cipla been studied?

Because Olanzapine Cipla is a generic medicine, studies in patients have been limited to tests to demonstrate that it is bioequivalent to the reference medicine, Zyprexa. Two medicines are bioequivalent when they produce the same levels of the active substance in the body.

## What are the benefits and risks of Olanzapine Cipla?

Because Olanzapine Cipla is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as the reference medicine's.

## Why has Olanzapine Cipla been approved?

The CHMP concluded that, in accordance with EU requirements, Olanzapine Cipla has been shown to have comparable quality and to be bioequivalent to Zyprexa. Therefore, the CHMP's view was that, as for Zyprexa, the benefit outweighs the identified risk. The Committee recommended that Olanzapine Cipla be given marketing authorisation.

## Other information about Olanzapine Cipla

The European Commission granted a marketing authorisation valid throughout the EU for Olanzapine Cipla on 14 November 2007. The name of the medicine was changed to Olanzapine Cipla on 16 May 2013.

The full EPAR for Olanzapine Cipla can be found on the Agency's website: [ema.europa.eu/FindMedicine/HumanMedicines/EuropeanPublicAssessmentReports](http://ema.europa.eu/FindMedicine/HumanMedicines/EuropeanPublicAssessmentReports). For more information about treatment with Olanzapine Cipla, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

The full EPAR for the reference medicine can also be found on the Agency's website.

This summary was last updated in 08-2013.